Inhibrx Biosciences, Inc. (INBX) — SEC Filings
Inhibrx Biosciences, Inc. (INBX) — 22 SEC filings. Latest: 8-K (Dec 16, 2025). Includes 10 8-K, 5 10-Q, 3 SC 13G.
View Inhibrx Biosciences, Inc. on SEC EDGAR
Overview
Inhibrx Biosciences, Inc. (INBX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: Inhibrx Biosciences, Inc. filed an 8-K on December 16, 2025, to report on various events. The filing includes information on financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, formerly known as Ibex SpinCo, Inc. until January 11, 2024, is incorpor
Sentiment Summary
Across 22 filings, the sentiment breakdown is: 20 neutral, 2 mixed. The dominant filing sentiment for Inhibrx Biosciences, Inc. is neutral.
Filing Type Overview
Inhibrx Biosciences, Inc. (INBX) has filed 10 8-K, 5 10-Q, 1 DEF 14A, 1 10-K, 3 SC 13G, 1 S-1, 1 SC 13D with the SEC between May 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (22)
Risk Profile
Risk Assessment: Of INBX's 19 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.3M |
| Net Income | $-107.221M |
| EPS | $-6.93 |
| Debt-to-Equity | 2.72 |
| Cash Position | $153.088M |
| Operating Margin | -8007.7% |
| Total Assets | $177.471M |
| Total Debt | $99.917M |
Key Executives
- Mark P. Lappe
- Kelly D. Deck C.P.A.
- Brendan P. Eckelman Ph.D.
- Mark Lappe
Industry Context
Inhibrx Biosciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel protein therapeutics. The industry is characterized by long development cycles, significant R&D investment, and a high rate of failure. Success hinges on innovation, clinical trial outcomes, and navigating complex regulatory pathways. Recent trends include increased M&A activity and a focus on specialized therapeutic areas.
Top Tags
biotech (5) · financials (4) · 10-Q (3) · 8-K (2) · Biotechnology (2) · Spin-off (2) · R&D Expenses (2) · Net Loss (2) · sec-filing (2) · disclosure (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $153.088M | as of September 30, 2025, stable from $152.596M at December 31, 2024 |
| Net loss | $107.221M | for the nine months ended September 30, 2025, compared to $1.735B net income in 2024 |
| Research and development expenses | $87.679M | for the nine months ended September 30, 2025, down from $170.376M in 2024 |
| General and administrative expenses | $17.723M | for the nine months ended September 30, 2025, down from $111.244M in 2024 |
| Long-term debt, net | $99.917M | as of September 30, 2025, up from zero at December 31, 2024 |
| Total revenue | $1.3M | for the nine months ended September 30, 2025, up from $0.1M in 2024 |
| Accumulated deficit | $213.353M | as of September 30, 2025, increased from $106.132M at December 31, 2024 |
| Proceeds from issuance of debt | $99.965M | for the nine months ended September 30, 2025 |
| Fair value of warrants issued to lender | $1.720M | in conjunction with 2025 Loan Agreement |
| Net loss for Q2 2025 | $28.65M | Significant decrease from $1.86B net income in Q2 2024 due to prior year's Sanofi transaction gain. |
| Net loss for H1 2025 | $71.97M | Compared to $1.78B net income in H1 2024, reflecting the post-spin-off financial structure. |
| License fee revenue for Q2 2025 | $1.3M | Increased from $0.1M in Q2 2024, showing a modest revenue stream. |
| Research and development expenses for Q2 2025 | $22.27M | Decreased significantly from $67.63M in Q2 2024, reflecting the spin-off of INBRX-101. |
| General and administrative expenses for Q2 2025 | $6.42M | Decreased substantially from $93.37M in Q2 2024, indicating reduced overhead post-transaction. |
| Cash and cash equivalents as of June 30, 2025 | $186.57M | Increased from $152.60M at December 31, 2024, bolstered by new debt. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Inhibrx Biosciences, Inc. (INBX)?
Inhibrx Biosciences, Inc. has 22 recent SEC filings from May 2024 to Dec 2025, including 10 8-K, 5 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INBX filings?
Across 22 filings, the sentiment breakdown is: 20 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Inhibrx Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Inhibrx Biosciences, Inc. (INBX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Inhibrx Biosciences, Inc.?
Key financial highlights from Inhibrx Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for INBX?
The investment thesis for INBX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Inhibrx Biosciences, Inc.?
Key executives identified across Inhibrx Biosciences, Inc.'s filings include Mark P. Lappe, Kelly D. Deck C.P.A., Brendan P. Eckelman Ph.D., Mark Lappe.
What are the main risk factors for Inhibrx Biosciences, Inc. stock?
Of INBX's 19 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Inhibrx Biosciences, Inc.?
Forward guidance and predictions for Inhibrx Biosciences, Inc. are extracted from SEC filings as they are enriched.